Skip to main content
Premium Trial:

Request an Annual Quote

TGen Awarded $15M for Pancreatic Cancer Drug Research, Including siRNA Project

NEW YORK, Oct. 20 (GenomeWeb News) - National Cancer Institute has awarded the Translational Genomics Research Institute a five-year, $15 million grant to research pancreatic cancer treatments, including siRNA research, TGen said today.

 

"Our goal is to develop one successful candidate molecule for each year of the grant that can be offered to patients in order to turn the tables on pancreatic cancer," Daniel Von Hoff, director of TGen's Translational Drug Development Division and the grant's principal investigator, said in a statement.

 

The funding will be applied to three related projects, TGen said. Its collaborators include the Arizona Cancer Center at the University of Arizona and the University of Texas M.D. Anderson Cancer Center, the institute said.

 

TGen's Cancer Drug Development Laboratory will use siRNA as an adjuvant therapy, and to identify additional drug targets and biomarkers. Researchers at University of Texas MD Anderson Cancer Center will test drugs to change tumor micro-environments in order to prevent growth. A project conducted at TGen aims to produce drugs that selectively kill tumor cells having genomic deletions.

 

Approximately 35,000 people in the US will be diagnosed with pancreatic cancer this year and 31,800 people will die, TGen said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.